Intuitive Surgical beats Q2 estimates with $2.89B revenue, 19% growth

Intuitive Surgical's second-quarter revenue rose 19% to $2.89 billion, beating the $2.81 billion consensus, as hospitals accelerated upgrades to its da Vinci 5 robotic platform and Ion procedure volumes surged. Adjusted earnings per share of $2.80 topped analyst estimates of $2.48 and compared with $2.19 a year earlier.

"The da Vinci 5 upgrade cycle is moving faster than we modeled, with utilization roughly 11% higher than the legacy Xi system," J.P. Morgan analyst Robbie Marcus wrote in a note following the results. "This is a multi-year catalyst for system placements and recurring revenue."

Procedure volume grew approximately 16% for the da Vinci platform and 39% for the Ion bronchoscopy system in the quarter. Recurring revenue from instruments, accessories and services — which accounts for more than 80% of total revenue — rose 23% year over year to $2.12 billion in the first quarter, a trend that likely continued into Q2. The company placed 232 da Vinci 5 systems in the first quarter alone, up from 147 a year earlier, signaling strong demand for the next-generation platform with Force Feedback technology and embedded artificial intelligence.

The results mark a sharp reversal from the stock's year-to-date performance. Intuitive shares have fallen roughly 30% in 2026, pushing the forward price-to-earnings multiple to about 36 times — a steep discount to the five-year average of 58 times. The selloff reflected concerns that GLP-1 obesity drugs could reduce bariatric surgery volumes and that longer instrument lifespans might pressure recurring revenue. The Q2 report suggests those fears may be overblown, as growth in general surgery, urology and lung biopsy procedures more than offset any bariatric headwinds.

Intuitive Surgical's competitive moat continues to widen. The da Vinci 5 introduces hardware-enabled AI and haptic feedback — Force Feedback technology that gives surgeons a physical sense of tissue resistance for the first time — creating a technical barrier that rivals will find difficult to replicate. Meanwhile, the Ion platform is moving the company upstream into diagnostics, with each lung biopsy procedure consuming single-use needles, vision probes and 3D planning software. The da Vinci SP (Single Port) system is gaining traction in urology and head-and-neck surgeries, allowing an entire surgical team to operate through a single 2.5-centimeter incision.

The company faces headwinds in international markets, including capital spending constraints in Europe and pricing pressure in China, which could moderate system placement growth outside the U.S. But the domestic upgrade cycle and expanding procedure volumes provide a strong base. At 36 times forward earnings, Intuitive Surgical trades at a premium to the broader medical device sector but well below its own historical average. If the company sustains its current growth trajectory, the valuation gap represents an opportunity for long-term investors.

This article is for informational purposes only and does not constitute investment advice.